# US 2021/0275559 A1 · Hygromycin a compounds and methods of treating spirochete diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275559 A1
- Document ID: US20210275559A1
- Status: Published application
- Kind: A1
- Application number: 17/269,189
- Filed: 2019-08-19
- Published: 2021-09-09
- Earliest claimed: 2018-08-20
- Assignees: Northeastern University
- Inventors: Kim LEWIS; Yu IMAI; Xiaoqian (Wendy) WU; Anthony D'ONOFRIO
- Web page: https://patentgrep.com/patent/US20210275559A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 31/04: Antibacterial agents
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention provides, among other things, compounds useful for treating spirochete diseases such as Lyme disease, as well as pharmaceutical formulations and/or environmental baits containing such compounds.

## Claims

### Claim 1

A method of treating a disease associated with a spirochete in an animal, comprising: administering to an animal in need of treatment thereof a compound, a salt of the compound, a hydrate of the compound, or a solvate of the compound thereof, the compound having a structure according to formula (I):
wherein R1 is H or OH or halogen; R2 is H or OH or halogen; R3 is H or OH or halogen; R4 is H or OH or halogen; R5 is H or OH or halogen; Y is —O— or —NH— or —CH2—; X is selected from the group consisting of
wherein A is C1 or C2 or C3 or C4 or C5 or C6 haloalkyl or C1 or C2 or C3 or C4 or C5 or C6 alkoxy or C1 or C2 or C3 or C4 or C5 or C6 alkyl,
thereby treating the disease associated with the spirochete.

### Claim 2 (depends on 1)

The method of claim 1, wherein the spirochete is selected from the group consisting of a Treponema species, Leptospira species, Borrelia species, and a Brachyspira species.

### Claim 3 (depends on 1)

The method of claim 1, wherein the disease associated with a spirochete is selected from the group consisting of leptospirosis, Lyme disease, relapsing fever, syphilis, yaws, intestinal spirochetosis, gingivitis and periodontitis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the disease associated with a spirochete is Lyme disease.

### Claim 5 (depends on 1)

The method of claim 1, wherein the animal is a human.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound is

### Claim 7 (depends on 1)

The method of claim 1, wherein the disease associated with a spirochete is Lyme disease, wherein the animal is a human, and wherein the compound is

### Claim 8

A method of killing and/or preventing the growth of a spirochete, comprising: contacting the spirochete with a compound, a salt of the compound, a hydrate of the compound or a solvate of the compound thereof, the compound having a structure according to formula (I):
wherein R1 is H or OH or halogen; R2 is H or OH or halogen; R3 is H or OH or halogen; R4 is H or OH or halogen; R5 is H or OH or halogen; Y is —O— or —NH— or —CH2—; X is selected from the group consisting of
wherein A is C1 or C2 or C3 or C4 or C5 or C6 haloalkyl or C1 or C2 or C3 or C4 or C5 or C6 alkoxy or C1 or C2 or C3 or C4 or C5 or C6 alkyl, thereby killing and/or preventing the growth of the spirochete.

### Claim 9 (depends on 8)

The method of claim 8, wherein the spirochete is selected from the group consisting of a Treponema species, a Leptospira species, a Borrelia species, or the and a Brachyspira species.

### Claim 10 (depends on 8)

The method of claim 8, wherein the spirochete is selected from the group consisting of Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, Borrelia bavariensis, Borrelia turcica, and Borrelia garinii.

### Claim 11 (depends on 8)

The method of claim 8, wherein the compound is

### Claim 12 (depends on 10)

The method of claim 10, wherein the spirochete is Borrelia burgdorferi and the compound, is

### Claim 13

(canceled)

### Claim 14 (depends on 2)

The method of claim 2, wherein the spirochete is a Borrelia species.

### Claim 15 (depends on 14)

The method of claim 14, wherein the Borrelia species is selected from the group consisting of Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, Borrelia garinii, Borrelia bavariensis, and Borrelia turcica.

### Claim 16 (depends on 15)

The method of claim 15, wherein the Borrelia species is Borrelia burgdorferi.

### Claim 17 (depends on 1)

The method of claim 1, wherein the compound is administered to the animal via an oral route or a parenteral route.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound is administered to the animal via an oral route.

### Claim 19 (depends on 17)

The method of claim 17, wherein the compound is administered to the animal via a parenteral route.

### Claim 20 (depends on 19)

The method of claim 19, wherein the parenteral route is selected from the group consisting of an intravascular route, a subcutaneous route, an intradermal route, an intramuscular route, a spinal route, and an intrathecal route.

### Claim 21 (depends on 1)

The method of claim 1, wherein the compound is administered in an amount from about 5 mg to about 250 mg/kg body weight of the animal.

### Claim 22 (depends on 21)

The method of claim 21, wherein the compound is administered in an amount from about 25 mg to about 150 mg/kg body weight of the animal.

### Claim 23 (depends on 21)

The method of claim 21, wherein the compound is administered at a dose of 250 mg/kg body weight of the animal

### Claim 24 (depends on 21)

The method of claim 21, wherein the compound is administered at a dose of 70 mg/kg body weight of the animal.

### Claim 25 (depends on 21)

The method of claim 21, wherein the compound is administered at a dose of 50 mg/kg body weight of the animal.

### Claim 26 (depends on 21)

The method of claim 21, wherein the compound is administered at a dose of 25 mg/kg body weight of the animal.

### Claim 27 (depends on 21)

The method of claim 21, wherein the compound is administered at a dose of 75 mg/kg body weight of the animal.

### Claim 28 (depends on 8)

The method of claim 8, wherein the spirochete is contacted with the compound at a concentration of 0.12 μg/ml.

### Claim 29 (depends on 8)

The method of claim 8, wherein the spirochete is contacted with the compound at a concentration of 0.25 μg/ml.

### Claim 30

A method of reducing Borrelia burgdorferi infection in an animal, the method comprising:
a. administering a compound to the animal, wherein the compound is
b. obtaining a tissue sample from the animal; and
c. measuring the number Borrelia burgdorferi cells in the tissue from the animal.

### Claim 31 (depends on 30)

The method of claim 30, wherein the compound is administered in an amount from about 5 mg to about 250 mg/kg body weight of the animal.
